Related Experiment Video

Updated: Apr 16, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Oxidative stress response in patients infected by diverse hepatitis C virus genotypes

Mohammad Hassan Khadem Ansari1, Mir-Davood Omrani2, Fatemeh Kheradmand3

  • 1Clinical Biochemistry Department, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, IR Iran.

Hepatitis Monthly
|March 20, 2015
PubMed

Insights

Hepatitis C virus (HCV) genotypes significantly impact oxidative stress levels. Genotype 1a/1b is linked to severe oxidative stress, while other genotypes show milder responses, suggesting tailored therapies.

Area of Science:

  • Hepatology
  • Virology
  • Biochemistry

Background:

  • The precise molecular mechanisms driving hepatitis C virus (HCV) pathogenesis are not fully understood.
  • Oxidative stress is a known factor in chronic HCV infection, but its correlation with specific HCV genotypes requires further investigation.

Purpose of the Study:

  • To investigate the impact of different HCV genotypes on oxidative status.
  • To compare oxidative stress markers between HCV patients and healthy controls.

Main Methods:

  • A case-control study involving 160 HCV patients with known genotypes and 160 healthy controls.
  • Measurement of oxidative stress markers: total antioxidant status (TAS), glutathione (GSH and GSSG), Gamma-glutamyl transferase (GGT), and malondialdehyde (MDA).

Main Results:

  • Significant differences in all measured oxidative stress markers were observed between HCV patients and controls (P < 0.05).
  • Distinct patterns of oxidant/antioxidant balance were identified across various HCV genotypes.
  • An increasing trend in antioxidant levels and a decreasing trend in oxidative markers (except MDA) were noted from genotype 1a/1b towards healthy controls.

Conclusions:

  • HCV genotype 1a/1b may be associated with more severe oxidative stress and potentially more serious disease.
  • Milder oxidative responses were observed in genotypes 4, 2a/c, 2b, and 3a.
  • Combined antiviral and antioxidative therapies could improve treatment outcomes for HCV patients, particularly those with more aggressive genotypes.
Abstract

Keywords:
AntioxidantGamma-Glutamyl TransferaseGlutathioneHepatitis CMalondialdehyde

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358